# A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers

> **NCT04232345** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 32 (actual)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction (HFpEF)

## Interventions

- **DRUG:** AZD4831
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04232345
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-16
- **Primary completion:** 2021-03-11
- **Final completion:** 2021-03-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2021-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04232345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04232345, "A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04232345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*